Navigation Links
USPTO Confirms Validity of Bystolic(R) Patent
Date:11/24/2008

NEW YORK, Nov. 24, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) announced today that the U.S. Patent and Trademark Office ("USPTO") has closed prosecution on the merits of the reexamination proceedings for the patent for Bystolic(R) and confirmed the validity of all of the previously granted claims. As a result, the USPTO has issued a Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Patent No. 6,545,040 (the '040 patent) to Janssen Pharmaceutica N.V., the patent holder. The Notice withdraws all of the enumerated rejections and confirms such validity. The '040 patent covers nebivolol, the active ingredient in Bystolic(R), a beta-blocker that is currently approved in the United States for the treatment of hypertension. The '040 patent expires in April 2020. Forest has applied for patent term extension for this patent until December 2021.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

About the Bystolic(R) License

Forest licensed U.S. and Canadian rights to nebivolol from Mylan Laboratories Inc. in January 2006. Forest markets nebivolol under the Bystolic trademark in the U.S. Mylan licensed the U.S. and Canadian rights to nebivolol from Janssen Pharmaceutica N.V. in February 2001, and has obtained Janssen's consent to sub-license nebivolol to Forest Laboratories in those territories.

About Forest Laboratories

Forest Laboratories (NYSE: FRX) is a U.S.-based pharmaceutical company with a long track record of building partnerships and developing and marketing products that make a positive difference in people's lives. In addition to its well-established franchises in therapeutic areas of the central nervous and cardiovascular systems, Forest's current pipeline includes product candidates in all stages of development and across a wide range of therapeutic areas. The company is headquartered in New York, NY. To learn more about Forest Laboratories, visit www.FRX.com.

Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and any subsequent SEC filings.


'/>"/>
SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. USPTO Issues Patent Embodying Methodologies for Abating a Broad Range of Allergens, Pathogens, Viruses, Bacteria, Odors and Volatile Organic Compounds.
2. Gentiva Health Services Confirms Management Succession
3. Study confirms increased heart attack deaths in NYC ambulance diversions
4. Report Confirms Consumer Selection is a Driving Force in Health Care Today
5. Breaking News: Finally! A Catholic Bishop Confirms that a Catholic Cannot Vote for Obama in Good Conscience
6. Study Confirms Effectiveness of Magnetic Therapy in Pain Relief
7. New Study Confirms Link Between Pain Pumps and Cartilage Damage -- Searcy Denney Law Firm Investigates Claims
8. Longs Drug Stores Confirms Receipt of Expression of Interest from Walgreens
9. Adhesion Prevention New Major Market Opportunity, Haemacure Confirms Effectiveness of its Fibrin Sealant in Second Preclinical Study in Adhesion Prevention in a Bleeding Model
10. Study confirms colorectal cancer screening should start at age 50
11. Pennsylvania Department of Health Confirms Rabid Kitten Found in York County
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Datta ... M.D. has joined the revolutionary endoscopic practice under Dr. Datta. Patel is a ... Pain Medicine. The patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic ...
(Date:4/28/2017)... ... April 28, 2017 , ... People are starting to ... “Wearing a hearing aid doesn’t have the stigma it had when great-grandpa wore his ... of Greater Boston, in a NALA North American Speaker Series (NASS) segment. ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... the Brooke Grove Foundation implement a Microsoft Dynamics GP solution that integrates to ... ERP expert that specializes in long-term care, Brooke Grove now has the capability ...
(Date:4/28/2017)... ... 2017 , ... Christie Medical Holdings, Inc. , with its market-leading ... Medical Inc. , a leader in infusion therapy and pain management. , Intravenous ... percent of hospital patients receiving a peripheral IV catheter as part of their treatment ...
(Date:4/27/2017)... ... April 27, 2017 , ... The American Brain Foundation ... Leadership in Neurology Award (PLINA). The couple joins a prestigious list of past ... Walter Mondale, actor Michael J. Fox and former U.S. Attorney General Janet Reno. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research and ... Pharmaceutical Contract Manufacturing Services Market Analysis By Service (Manufacturing, Research), ... Forecasts, 2014 - 2025" report to their offering. ... The Latin American pharmaceutical ... billion by 2025 Low drug registration cost in ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
(Date:4/19/2017)... Global Prostate Cancer Therapeutics Market: Overview ... cancer therapeutics market analyzes the current and future ... prostate cancer, launch of promising emerging therapies, as ... drugs & therapeutic biological products, and high growth ... side effects are some of the drivers expected ...
Breaking Medicine Technology: